Top Radiopharmaceutical Manufacturers
.png)
Published: July 2024
The innate expertise, and availability of the required capabilities and infrastructure enable the CMOs to effectively fulfil the requirements of their clients pertaining to the production of radiopharmaceuticals. We analyzed over 210 radiopharmaceutical manufacturers that are engaged in their manufacturing. In this article, discover 7 top radiopharmaceutical manufacturers and their capabilities in this industry
In the realm of modern medicine, nuclear medicine has emerged as a promising and advanced tool that can be used for the diagnosis and treatment of diseases. Nuclear medicine involves the use of radiopharmaceuticals or radiotracers in which radioisotopes are bound to biological molecules that can target specific organs, tissues, or cells within the human body. Presently, nuclear reactors and particle accelerators are used to produce a wide array of radiopharmaceuticals for diagnostic and therapeutic applications. Further, innovative chemistry and automated synthesis devices have been designed to produce a multitude of novel radiopharmaceuticals for both imaging and treatment. In addition, high-resolution and high-sensitivity instruments have been developed to assess normal psychological processes, measure the distribution of drugs and monitor treatment effectiveness in living systems.
The extent to which a radioactive substance is absorbed by a particular organ or tissue indicates the level of function of the organ or tissue being studied. This can be detected by the two most common imaging modalities used in the field of nuclear medicine, namely, Single Photon Emission Computed Tomography (SPECT) and Positron Emission Tomography (PET) scans. In SPECT scans, the computers generate three-dimensional (3D) (tomographic) images of the distribution of radiopharmaceuticals that have been injected in the patient’s body. The radiotracer injected emits gamma light, having a comparatively lower wavelength than visible light. Therefore, SPECT imagers are equipped with camera detectors that detect the electromagnetic radiations emitted by the tracers and help in generating 3D images. Similar to SPECT, PET scans also utilize radiopharmaceuticals to create 3D images. However, the type of radiotracers injected into the patient body are different in both the imaging techniques. The PET imaging technique uses a small amount of radiotracer which starts to decay and produces small particles known as positrons. These positrons annihilate with the electrons in patient’s body and produces a small amount of energy in the form of two photons that shoot-off in opposite directions. The detectors in the PET scanner measure the energy emitted by the photons and use this information to generate images of the internal organs.
With the increase in demand for radiopharmaceuticals, pharmaceutical companies started investing in the discovery and innovation of these advanced medicines. It is worth highlighting that the production of radiopharmaceuticals, in comparison to traditional pharmaceuticals, is more complex and requires specialized facilities, equipment and operational expertise. The complete process of radiopharmaceutical product development is multifaceted, and selecting a suitable CMO for outsourcing different operations is one of the primary challenges faced by the stakeholders in this domain. Similar to the area of cytotoxic drugs and HPAPI manufacturing, It is worth noting that most of the contract radiopharmaceutical manufacturers also have profound experience in niche and emerging areas, in terms of different types of radiopharmaceuticals manufactured. In addition, the innate expertise and availability of required capabilities, enables such service providers to offer a broader range of specialized expertise, including cutting-edge equipment and facilities, and cost-effective solutions to their clients.
Roots Analysis has conducted an exhaustive study on Radiopharmaceutical Manufacturing Market featuring the current market landscape and future opportunity for the radiopharmaceutical manufacturers that are engaged in the this nuclear medicine and radiopharmaceutical manufacturing domain, over a span of 12 years.
Table of Contents
Below, we have listed (in alphabetical order), the top 7 radiopharmaceutical manufacturers.
- Advanced Accelerator Applications
- Cardinal Health
- DuChemBio
- Eckert & Ziegler
- ITM Isotope Technologies Munich
- Nihon Medi-Physics
- PharmaLogic
Interested in exploring all 210+ radiopharmaceutical manufacturers and their recent initiatives?
Discover Below the Details on 7 Top Radiopharmaceutical Manufacturers
Let us deep dive to understand the activity of the 7 top radiopharmaceutical manufacturers (shortlisted on the basis of manufacturing of theranostic radiopharmaceuticals and year of establishment (1971-2002)) in the nuclear medicine and radiopharmaceutical manufacturing market. It is essential to note that the selection of top players can differ substantially according to the defined criteria.
Through its own Wide Distribution Network, Advanced Accelerator Applications is Committed to Deliver Radiopharmaceutical Products Across 30 Countries
1. Advanced Accelerator Applications
Advanced Accelerator Applications, a Novartis company, is a global pharmaceutical company specializing in nuclear medicine. Leveraging its elaborate portfolio of nuclear medicine, the company claims to provide radiopharmaceuticals for a wide range of disorders, including oncological, cardiovascular, neurological, infectious and inflammatory disorders. It is worth highlighting that the company ensures the global availability of its innovative diagnostic and therapeutic products. In addition, the company claims to have the required capabilities to offer contract services for the development and manufacturing of a wide range of radiopharmaceuticals.
Advanced Accelerator Applications: Company Details
| Key Parameters | Description |
| Company Logo |  |
| Year of Establisment | 2002 |
| Number of Employees | 1,001-5,000 |
| Headquarter |  |
Advanced Accelerator Applications: List of Radiopharmaceuticals and Location of Manufacturing Facilities
| Type of Radiopharmaceutical Manufactured | |
| Diagnostic Radiopharmaceuticals | Details |
| PET Radiopharmaceuticals |
|
| Therapeutic Radiopharmaceuticals | Details |
| Beta Emitters | Leutetium-177 |
| Manufacturing Facilities | |
| Number of Manufacturing Facilities | 18 |
| Type of Radiopharmaceutical Manufactured | |
| Location of Manufacturing Facilities |
|
Advanced Accelerator Applications offer following radiopharmaceutical manufacturing services:
- Product Synthesis / Formulation
- Production of Cold Kits
Recent Initiatives by Advanced Accelerator Applications Focusing on Nuclear Medicine and Radiopharmaceutical Manufacturing Domain: In January 2024, the company expanded its radiopharmaceutical manufacturing operations through the addition of a new 70,000 square feet facility in Indianapolis, US.
Further details on recent initiatives taken by Advanced Accelerator Applications as well as other radiopharmaceutical manufacturers have been provided in detail in the report.
Cardinal Health Claims to be the Only US National Source for SPECT and PET Radiopharmaceuticals
2. Cardinal Health
Cardinal Health is a global healthcare company that operates through two business segments, namely, pharmaceutical, and medical segment. Within the pharmaceutical segment, the company offers generic and branded pharmaceuticals, over-the-counter healthcare products, and radiopharmaceuticals to its customers. It is worth highlighting that the company delivers more than 12 million radiopharmaceutical doses annually through 130+ nuclear pharmacies located across the globe. In addition, the company claims to have the end-to-end capabilities to offer contract services for the development and manufacturing of a wide range of radiopharmaceuticals.
Cardinal Health: Company Details
| Key Parameters | Description |
| Company Logo |  |
| Year of Establisment | 1971 |
| Number of Employees | 10,001+ |
| Headquarter |  |
Cardinal Health: List of Radiopharmaceuticals and Location of Manufacturing Facilities
| Type of Radiopharmaceutical Manufactured | |
| Diagnostic Radiopharmaceuticals | Details |
| SPECT Radiopharmaceuticals |
|
| PET Radiopharmaceuticals |
|
| Therapeutic Radiopharmaceuticals | Details |
| Alpha Emitters | Radium-223 |
| Beta Emitters |
|
| Manufacturing Facilities | |
| Number of Manufacturing Facilities | 30 |
| Location of Manufacturing Facilities | All facilities are located in the US |
Cardinal Health offer following radiopharmaceutical manufacturing services:
- Product Synthesis / Formulation
- Process Development
- Scale-Up
- Analytical Services
- Quality Control
- Technology Transfer
- Regulatory Support
- Feasibility Studies
- Supply Chain
- Production of Cold Kits
- Packaging
Recent Initiatives by Cardinal Health Focusing on Nuclear Medicine and Radiopharmaceutical Manufacturing Domain: In June 2024, the company participated in the Society of Nuclear Medicine & Molecular Imaging (SNMMI) 2024 Annual Meeting, which was held in Toronto, Canada.
Further details on recent initiatives taken by Cardinal Health as well as other radiopharmaceutical manufacturers have been provided in detail in the report.
DuChemBio Claims to Have the Largest Radiopharmaceutical Manufacturing Network in South Korea
3. DuChemBio
DuChemBio is a technology-driven contract development and manufacturing organization that possess the required capabilities for the development and manufacturing of diagnostic, therapeutic and theranostic radiopharmaceuticals. The company has established 12 radio-pharmacy facilities in South Korea and its service portfolio includes services related manufacturing, technology transfer, packaging, purification and supply of radiopharmaceuticals at preclinical, clinical and commercial scale. The company claims to be the only developer of GEP-NET therapeutic radiopharmaceutical in South Korea.
It is worth highlighting that the company’s drug development pipeline has several promising candidates for different oncological and neurological disorders including prostate cancer, breast cancer and dementia. With a strong focus on research and development, along with a robust drug pipeline, the company strives to offer safe, effective and convenient radiopharmaceuticals for various disease indications.
DuChemBio: Company Details
| Key Parameters | Description |
| Company Logo |  |
| Year of Establisment | 2002 |
| Number of Employees | 51-200 |
| Headquarter |  |
DuChemBio: List of Radiopharmaceuticals and Location of Manufacturing Facilities
| Type of Radiopharmaceutical Manufactured | |
| Diagnostic Radiopharmaceuticals | Details |
| PET Radiopharmaceuticals |
|
| Manufacturing Facilities | |
| Number of Manufacturing Facilities | 6 |
| Location of Manufacturing Facilities | All facilities are located in South Korea |
DuChemBio offer following radiopharmaceutical manufacturing services:
- Product Synthesis / Formulation
- Technology Transfer
- Consulting Services
- Supply Chain
- Production of Cold Kits
- Packaging
- Purification
Recent Initiatives by DuChemBio Focusing on Nuclear Medicine and Radiopharmaceutical Manufacturing Domain: In June 2022, the company entered into collaboration with ImaginAb, in order to manufacture and distribute ImaginAb’s CD8 ImmunoPET agent (89Zr-crefmirlimab berdoxam), a zirconium labelled antibody
Further details on recent initiatives taken by DuChemBio as well as other radiopharmaceutical manufacturers have been provided in detail in the report.
Eckert & Ziegler is Expanding its Presence in Radiopharmaceutical Industry Across Geographies; Its GalliaPharm® Generator Will be Utilized in a Clinical Research Project in Japan
Eckert & Ziegler
Eckert & Ziegler is a technology-driven company that operates through two business segments, namely, medical, and radioisotope segment. Within the medical segment, the company offers radiopharmaceuticals, radiochemicals and medical devices for the diagnosis and treatment of oncological and neurological disorders. In addition, the company claims to have end-to-end capabilities to offer contract services for the development and manufacturing of a wide range of radiopharmaceuticals (including diagnostic, therapeutic and theranostic radiopharmaceuticals). As per the company’s website, it also conducts customized studies on radiopharmaceuticals for clinical trials.
In January 2024, the company announced its collaboration with ARTBIO in order to support in the establishment of manufacturing and delivery of latter company’s alpha radioligand therapies using its proprietary AlphaDirectTM Lead-212 (Pb-212) isolation technology.
Eckert & Ziegler: Company Overview
| Key Parameters | Description |
| Company Logo |  |
| Year of Establisment | 1997 |
| Number of Employees | 51-200 |
| Headquarter |  |
Eckert & Ziegler: List of Radiopharmaceuticals and Location of Manufacturing Facilities
| Type of Radiopharmaceutical Manufactured | |
| Diagnostic Radiopharmaceuticals | Details |
| SPECT Radiopharmaceuticals |
|
| PET Radiopharmaceuticals |
|
| Therapeutic Radiopharmaceuticals | Details |
| Alpha Emitters |
|
| Beta Emitters |
|
| Manufacturing Facilities | |
| Number of Manufacturing Facilities | 2 |
| Location of Manufacturing Facilities |
|
Eckert & Ziegler offer following radiopharmaceutical manufacturing services:
- Product Synthesis / Formulation
- Process Development
- Scale-Up
- Quality Control
- Consulting Services
- Regulatory Support
- Feasibility Studies
- Supply Chain
- Production of Cold Kits
- Waste Management
- Packaging
- Stability Studies
Recent Initiatives by Eckert & Ziegler Focusing on Nuclear Medicine and Radiopharmaceutical Manufacturing Domain: In February 2024, the company announced the expansion of its radioisotope supply business in Japan through its support (along with Novartis Pharma) in a clinical trial for Ga-68 labeled diagnostics.
Further details on recent initiatives taken by Eckert & Ziegler as well as other radiopharmaceutical manufacturers have been provided in detail in the report.
ITM Isotope Technologies Munich Thrives to Provide New Generation of Radiomolecular Precision Therapeutics and Diagnostics for Hard-To-Treat Tumors
ITM Isotope Technologies Munich
ITM Isotope Technologies Munich claims to be a pioneer in the field of radiopharmaceuticals. The company has expertise in the development, production and distribution of innovative targeted radiopharmaceuticals. Further, the company is involved in the research and development of innovative radiotherapies for diagnosis and treatment of various oncological disorders. Additionally, the company also offers radiolabeling equipment for the production of radiopharmaceuticals in hospitals and clinics. It is worth mentioning that the company recently received fast track designation for its novel therapeutic radionuclide, Lu-Edotreotide177 intended for the treatment of neuroendocrine tumors (NETs).
ITM Isotope Technologies Munich: Company Overview
| Key Parameters | Description |
| Company Logo |  |
| Year of Establisment | 2004 |
| Number of Employees | 501-1000 |
| Headquarter |  |
ITM Isotope Technologies Munich: List of Radiopharmaceuticals and Location of Manufacturing Facilities
| Type of Radiopharmaceutical Manufactured | |
| Diagnostic Radiopharmaceuticals | Details |
| PET Radiopharmaceuticals |
|
| Therapeutic Radiopharmaceuticals | Details |
| Alpha Emitters |
Actinium-225 |
| Beta Emitters |
|
| Manufacturing Facilities | |
| Number of Manufacturing Facilities | 2 |
| Location of Manufacturing Facilities | All facilities are located in Germany |
ITM Isotope Technologies Munich offer following radiopharmaceutical manufacturing services:
- Product Synthesis / Formulation
- Supply Chain
- Radiolabeling
Recent Initiatives by ITM Isotope Technologies Munich Focusing on Nuclear Medicine and Radiopharmaceutical Manufacturing Domain: In June 2024, the company raised EUR 188 million in an equity investment (led by Temasek) in order to advance and expand its radiopharmaceutical pipeline and prepare for the potential market launch of ITM-11 (n.c.a. 177Lu-edotreotide) for the treatment of gastroenteropancreatic NETs.
Further details on recent initiatives taken by ITM Isotope Technologies Munich as well as other radiopharmaceutical manufacturers have been provided in detail in the report.
With Strategic Collaborations with Academic Players, Nihon Medi-Physics has been Focused on Opening New Possibilities for Nuclear Medicine in Diagnostics
Nihon Medi-Physics
Headquartered in Japan, Nihon Medi-Physics is a radiopharmaceutical company specialized in providing medical imaging and radiotherapy solutions. The company is engaged in providing services for the research, development and manufacturing of a wide range of radiopharmaceuticals including diagnostic, therapeutic and theranostic radiopharmaceuticals. It is worth highlighting that, in 2022, the USFDA has accepted the company’s investigational new drug application to initiate a phase-I clinical trial for its theranostic imaging agent NMK89. As per the company’s website, the company also offers PET imaging tests for animal studies in cooperation with Sumika Chemical Analysis Service.
Nihon Medi-Physics: Company Overview
| Key Parameters | Description |
| Company Logo |  |
| Year of Establisment | 1973 |
| Number of Employees | 501-1000 |
| Headquarter |  |
Nihon Medi-Physics: List of Radiopharmaceuticals and Location of Manufacturing Facilities
| Type of Radiopharmaceutical Manufactured | |
| Diagnostic Radiopharmaceuticals | Details |
| PET Radiopharmaceuticals | Fluorine-18 Zirconium-89 Carbon-11 |
| Therapeutic Radiopharmaceuticals | Details |
| Alpha Emitters |
Actinium-225 |
| Gamma Emitters | Iodine-125 |
| Manufacturing Facilities | |
| Number of Manufacturing Facilities | 3 |
| Location of Manufacturing Facilities | All facilities are located in Japan |
Nihon Medi-Physics offer following radiopharmaceutical manufacturing services:
- Product Synthesis / Formulation
- Supply Chain
- Animal Studies
Recent Initiatives by Nihon Medi-Physics Focusing on Nuclear Medicine and Radiopharmaceutical Manufacturing Domain: In 2024, the company announced to support 2024-2026 Wagner-Torizuka Fellowship for Japanese physicians in the US and Canada, in order to provide experience and training in nuclear medicine / molecular imaging modalities in the areas of cardiology, neurology, and oncology.
Further details on recent initiatives taken by Nihon Medi-Physics as well as other radiopharmaceutical manufacturers have been provided in detail in the report.
PharmaLogic Is Engaged in the Expansion of its Radiopharmaceutical Portfolio, through Opening of Various Manufacturing Facilities and Extensively Collaborating with Industry Players in Nuclear Medicine Domain
PharmaLogic
PharmaLogic is a US-based contract development and manufacturing organization that is engaged in the development and production of a wide range of radiopharmaceuticals. Leveraging its elaborate service portfolio, the company claims to offer end-to-end product development services, ranging for preclinical development to commercialization of diagnostic, therapeutic and theranostic radiopharmaceuticals. It is worth highlighting that the company uses its own distribution network to deliver its radiopharmaceutical doses across North America.
PharmaLogic: Company Overview
| Key Parameters | Description |
| Company Logo |  |
| Year of Establisment | 1993 |
| Number of Employees | 501-1000 |
| Headquarter |  |
PharmaLogic: List of Radiopharmaceuticals and Location of Manufacturing Facilities
| Type of Radiopharmaceutical Manufactured | |
| Diagnostic Radiopharmaceuticals | Details |
| PET Radiopharmaceuticals |
|
| Therapeutic Radiopharmaceuticals | Details |
| Alpha Emitters | Lead-212 |
| Manufacturing Facilities | |
| Number of Manufacturing Facilities | 1 |
| Location of Manufacturing Facilities | US |
PharmaLogic offer following radiopharmaceutical manufacturing services:
- Product Synthesis / Formulation
- Process Development
- Quality Control
- Technology Transfer
- Regulatory Support
- Supply Chain
- Stability Studies
Recent Initiatives by PharmaLogic Focusing on Nuclear Medicine and Radiopharmaceutical Manufacturing Domain: In May 2024, the company announced the opening of radiopharmaceutical production facility in Bronx, New York.
Further details on recent initiatives taken by PharmaLogic as well as other radiopharmaceutical manufacturers have been provided in detail in the report.
What About the Other Radiopharmaceutical Manufacturers Around the World?
The above presentation features seven top radiopharmaceutical manufacturers selected from a pool of over 210 industry and non-industry players that we have compiled. If you're interested, you can download the Sample Report on this topic by Roots Analysis. For personalized assistance in identifying the most relevant solutions based on your specific criteria, please don't hesitate to reach out to us at sales@rootsanalysis.com.
Sources:
- https://www.novartis.com/us-en/news/media-releases/novartis-expands-production-pluvicto-addition-its-largest-and-most-advanced-radioligand-therapy-manufacturing-facility-indianapolis
- https://s15.a2zinc.net/clients/SNMMI/SNMMI24/public/eBooth.aspx?IndexInList=1&FromPage=Exhibitors.aspx&ParentBoothID=&ListByBooth=true&BoothID=105915
- https://imaginab.com/news-events/news/imaginab-and-duchembio-announce-manufacturing-and-distribution-partnership/
- https://www.ezag.com/home/press/press_releases/detail/?tx_ttnews%5Btt_news%5D=1794&cHash=71e97184a035f871ad7960e399ec5eb4
- https://www.itm-radiopharma.com/news/press-releases/press-releases-detail/itm-raises-eur188m-to-enhance-radiopharmaceutical-pipeline-and-to-strengthen-leading-position-in-medical-radioisotope-manufacturing-671/
- https://snmmi.org/Web/Research-Publications/Grants-Awards-and-Scholarships/Default.aspx
- https://www.radiopharmacy.com/press-releases/pharmalogic-announces-opening-of-radiopharmaceutical-production-facility-in-new-york-city